成都普瑞法科技开发有限公司欢迎您!
ISO ISO
CNAS CNAS
高新技术企业 高新技术企业
USP USP
知识产权管理体系认证证书 知识产权管理体系认证证书

文献列表

专业生产定制高含量植提产品和中药成分

您当前的位置:
期刊名:RSC Advances
文献编号:
文献地址:
发表日期: December 2017
Glucocorticoid resistance (GCR) remains a significant problem and is the most important reason for treatment failure of glucocorticoids (GCs). How to increase the sensitivity to GCs and exploring new agents to overcome GCR is of great significance. Herein, we report for the first time that the effects of combination of icariin and oleanolic acid (OA) on dexamethasone (Dex)-induced glucocorticoid receptor (GR) impairment in vivo and in vitro. Compared with the use of Dex or combination of icariin and OA alone, co-administration resulted in a significant increase in apoptosis, GR protein, GR binding and GRa protein both in GC-sensitive CEM-C7 and GC-resistant CEM-C1 cells and a decrease in GRb protein and GRb/GRa only in CEM-C1 cells. Furthermore, an ovalbumin-induced rat asthma model was chosen to evaluate the effects of co-administration of Dex and combination of icariin and OA in vivo. Compared with the use of Dex alone, co-administration could protect blood lymphocyte from excessive apoptosis, significantly increasing GR binding, GR protein and mRNA of GRa while decreasing GRb protein and mRNA of GRb. The results suggested that combination of icariin and OA could increase sensitivity to GCs through attenuating in vivo and in vitro Dex-induced GR impairment


Icariin [98% purity, as veried by high-performance liquid chromatography (HPLC)] and oleanolic acid (99.44% purity, as veried by HPLC) used in this study were purchased from Chengdu Biopurify Phytochemicals Ltd. (Chendu, China). 2.2 … 
 
相关产品